<DOC>
	<DOCNO>NCT01592084</DOCNO>
	<brief_summary>The role hyperlipidemia lipid lower therapy ( LLT ) Amyotrophic Lateral Sclerosis ( ALS ) pathophysiology impact disease progression survival unclear . The investigator analyze correlation lipid level disease progression survival ALS patient association LLT outcomes .</brief_summary>
	<brief_title>Hyperlipidemia Statin Therapy Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>A clinical diagnosis laboratorysupported probable , probable , definite familial , sporadic ALS , accord modify El Escorial criterion ( ref ) , study investigator Time disease onset less three year 18 year age Subjects diagnosis hyperlipidemia and/or take lipid lower medication exclude study . Requirement tracheotomy ventilation noninvasive ventilation &gt; 23 hour per day Diagnosis neurodegenerative disease ( Parkinson disease , Alzheimer disease , etc ) A clinically significant history significant medical illness ( advanced cancer , chronic inflammatory/infectious condition , etc ) within six month baseline Use progestins , anabolic steroid , corticosteroid within 45 day baseline visit . Therapy allow medically indicate baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>lipid lower therapy</keyword>
	<keyword>survival</keyword>
	<keyword>ALSFRS</keyword>
	<keyword>age</keyword>
	<keyword>BMI</keyword>
	<keyword>weight</keyword>
</DOC>